NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering innovative therapies that transform the lives of patients with rare diseases, today reported its results for the quarter ended June 30, 2014.
NPS Pharma reported net global Gattex®/Revestive® sales of $22.0 million for the second quarter of 2014, compared to $4.8 million for the same period last year. NPS Pharma continues to expect to achieve full-year 2014 global net sales of $100 to $110 million representing more than 200 percent year-over-year growth.
Help employers find you! Check out all the jobs and post your resume.
